Elanco Animal Health Incorporated Unrealized Gain (Loss) on Investments
Elanco Animal Health Incorporated (ELAN) reported Unrealized Gain (Loss) on Investments of -$8.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2023-03-01
- Elanco Animal Health Incorporated unrealized gain (loss) on investments for fiscal 2022 was -$8.00M.
- Elanco Animal Health Incorporated unrealized gain (loss) on investments for fiscal 2021 was -$10.00M, a 190.91% decline from fiscal 2020.
- Elanco Animal Health Incorporated unrealized gain (loss) on investments for fiscal 2020 was $11.00M.
- Elanco Animal Health Incorporated unrealized gain (loss) on investments for fiscal 2019 was $0.00.
| Period end | Unrealized Gain (Loss) on Investments 12 month |
|---|---|
| 2022-12-31 | -$8.00M 10-K · filed 2023-03-01 |
| 2021-12-31 | -$10.00M 10-K · filed 2023-03-01 |
| 2020-12-31 | $11.00M 10-K · filed 2023-03-01 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |